Loading
There is an agreed international list of what should be checked in someone who has had a transplant, and how often, and an accreditation system that centres are inspected against. What there is much less of is a guarantee that any individual survivor is receiving the checks. Knowing the list exists lets a person ask for it.
The screening recommendations. An international group of transplant experts convened in 2011 and published updated recommendations for screening and preventive practices for long-term survivors after transplant, updating a 2006 document, covering both paediatric and adult survivors of autologous and allogeneic transplant, written to be internationally applicable. This is the document behind most of the surveillance referred to elsewhere in this file: bone density, thyroid function, lipids and glucose, pulmonary function, ophthalmological assessment, iron status, gonadal function, cancer screening, vaccination and psychosocial assessment, each with a recommended population and interval. It is a consensus document drawing on the evidence available, not a set of randomised trial results, and it says so.
The accreditation standards. FACT, the Foundation for the Accreditation of Cellular Therapy, and JACIE, the Joint Accreditation Committee ISCT-Europe and EBMT, publish joint international standards. The FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration are in their ninth edition, and a separate set, the FACT-JACIE International Standards for Immune Effector Cells, in its third edition, covers programmes delivering CAR-T and other immune effector cells without hematopoietic transplantation. FACT describes these as covering hematopoietic progenitor cells from any tissue source, nucleated and mononuclear cells, immune effector cells and genetically modified cells. Accreditation is voluntary in principle; in practice, in Europe, JACIE accreditation is required for transplant activity in a number of countries and is widely treated as a condition of commissioning, and manufacturers of commercial CAR-T products require centre qualification before a product is released to them.
What accreditation does and does not guarantee is worth stating. It inspects the programme: quality management, staffing, training, chain of identity, data submission to a registry, and the existence of defined procedures including for long-term follow-up. It does not inspect whether a named survivor had a DXA scan last year.
The registries. The CIBMTR in the United States and the EBMT in Europe collect outcome data on transplants and, increasingly, on cellular therapies. Data submission is a standards requirement, and the registries are where the survival curves, the second cancer rates and the chronic GvHD incidence trends in this file come from. A survivor is, in effect, contributing to the evidence base that will describe the next cohort, which is an argument for staying in follow-up that is rarely put to people directly.
What a survivor is offered, in the US and the UK. In the United States, long-term follow-up is usually run by the transplant centre, often through a dedicated survivorship clinic at larger centres, with the recommendations above as the template; access depends on insurance and on distance, and transfer back to primary care is where surveillance is most often lost. In the United Kingdom, transplant activity is commissioned by NHS England from accredited centres and long-term follow-up is conducted by those centres and shared with general practice, with the British Society of Blood and Marrow Transplantation and Cellular Therapy publishing guidance for its members. An honest note on sourcing: the NHS England service specification page for haematopoietic stem cell transplantation did not return readable content to an automated request while this record was written, so the UK arrangements described here are taken from the BSBMTCT and from the published UK joint consensus statement on revaccination rather than from the commissioning document itself. A reader who needs the current UK specification should go to NHS England directly.
The gap this record exists to name. There is a published list of what should be done, an inspected standard for the programmes that should do it, and registries that record outcomes. There is no mechanism in either country that reliably tells an individual survivor, ten years out and living two hundred miles from the transplant centre, which tests they are due this year. The survivorship care plan, which OnCo covers on `survivorship-care-plan`, is the instrument designed to close that gap, and it works only if someone writes one.
Long-term safety in a small, highly specialised population cannot be assured by individual clinical judgement, because no single clinician sees enough survivors to recognise a pattern. It is assured instead by three linked mechanisms: a consensus list of what to look for, an inspected standard for the programmes that look, and registries that aggregate what is found so the list can be revised. The weak link is the handover from the specialist programme to generalist care.
Query for this technology: (TITLE:"Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered" OR ABSTRACT:"Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered" OR TITLE:"long-term follow-up after transplant" OR ABSTRACT:"long-term follow-up after transplant" OR TITLE:"EBMT recommendations" OR ABSTRACT:"EBMT recommendations" OR TITLE:"CIBMTR screening recommendations" OR ABSTRACT:"CIBMTR screening recommendations") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, not a curated reading list.
Shares The lungs after transplant: bronchiolitis obliterans syndrome, Bone, eyes, kidneys and lungs after transplant, Second cancers after allogeneic transplant, After a transplant or cell therapy: what to ask for and the tags rejuvenation, survivorship, transplant.
Shares AlloCare: a stepped-care late-effects service after allogeneic transplant, Late effects after a stem cell transplant, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares Survival after transplant, and why the curve never quite rejoins the population, The lungs after transplant: bronchiolitis obliterans syndrome, Second cancers after allogeneic transplant, Late effects after a stem cell transplant and the tags rejuvenation, survivorship, transplant.
Shares Bone, eyes, kidneys and lungs after transplant, Late effects after a stem cell transplant, After a transplant or cell therapy: what to ask for, Autologous stem cell transplant (high-dose therapy) and the tags rejuvenation, survivorship, transplant.
Shares Long-term follow-up for gene-modified cell products: fifteen years, and why, Second cancers after allogeneic transplant, After a transplant or cell therapy: what to ask for, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, transplant.
Shares The lungs after transplant: bronchiolitis obliterans syndrome, After a transplant or cell therapy: what to ask for, Quality of life, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Revaccination after transplant: the schedules, and where the UK and the US differ, After a transplant or cell therapy: what to ask for, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares Revaccination after transplant: the schedules, and where the UK and the US differ, After a transplant or cell therapy: what to ask for, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.